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Background. The live smallpox and Bacillus Calmette-Guérin (BCG) vaccinations have been associated with better adult sur-
vival in both Guinea-Bissau and Denmark. In Guinea-Bissau, human immunodeficiency virus (HIV)-1 became an important cause 
of death after smallpox vaccination was phased out globally in 1980. We hypothesised that smallpox and BCG vaccinations were 
associated with a lower prevalence of HIV-1 infection, and we tested this hypothesis in both Guinea-Bissau and Denmark.
Methods. We conducted 2 studies: (1) a cross-sectional study of HIV infection and vaccination scars in Guinea-Bissau including 
1751 individuals and (2) a case-base study with a background population of 46 239 individuals in Denmark. In Guinea-Bissau, HIV-1 
transmission was almost exclusively sexually transmitted. In Denmark, we excluded intravenous drug users. Data were analyzed 
using logistic regression.
Results. Bacillus Calmette-Guérin and/or smallpox vaccination compared with neither of these vaccines was associated with 
an adjusted odds ratio (aOR) for HIV-1 of 0.62 (95% confidence interval [CI], 0.36–1.07) in Guinea-Bissau and 0.70 (95% CI, 
0.43–1.15) in Denmark. We combined the results from both settings in a meta-analysis (aOR = 0.66; 95% CI, 0.46–0.96). Data from 
Guinea-Bissau indicated a stronger effect of multiple smallpox vaccination scars (aOR = 0.27; 95% CI, 0.10–0.75) as follows: women, 
aOR = 0.18 (95% CI, 0.05–0.64); men, aOR = 0.52 (95% CI, 0.12–2.33); sex-differential effect, P = .29.
Conclusions. The studies from Guinea-Bissau and Denmark, 2 very different settings, both suggest that the BCG and smallpox 
vaccines could be associated with a decreased risk of sexually transmitted HIV-1. It might be informative to pursue this observation 
and explore possible protective mechanisms as part of the search for an HIV-1 vaccine.
Keywords. BCG vaccine; heterologous immunity; HIV-1; nonspecific effects of vaccines; smallpox vaccine. 
In 1980, the world ceased to use the live-attenuated smallpox 
vaccine [1]. Previous studies did not investigate whether stop-
ping smallpox vaccine affected general health. However, subse-
quent studies have shown that live vaccines may have beneficial 
nonspecific or heterologous effects (NSEs), which may be medi-
ated via training of the innate immune system and provide 
cross-protection against unrelated pathogens [2, 3].
With respect to potential NSEs of smallpox vaccine, 2 stud-
ies in Guinea-Bissau showed lower mortality among individu-
als with smallpox vaccination scars compared with individuals 
with no vaccination scars 20–25 years after smallpox vaccina-
tion stopped [4, 5]. The beneficial association increased with 
the number of smallpox vaccination scars and was most 
pronounced in women. In Denmark, register-based studies 
showed that smallpox vaccination was associated with reduced 
incidence of all-cause infectious disease hospitalization [6], 
and smallpox vaccination as well as Bacillus Calmette-Guérin 
(BCG) vaccinations were associated with lower risk of death 
due to natural causes [7].
Human immunodeficiency virus (HIV)-1 was first regis-
tered in Guinea-Bissau in the late 1980s after smallpox vacci-
nation had stopped [1]. Human immunodeficiency virus-1 
subsequently became a common cause of adult death. With 
the failure to produce an effective HIV vaccine, and with the 
knowledge that smallpox vaccine reduced all-cause mortality, 
we hypothesized that having been smallpox vaccinated was 
associated with protection against contracting HIV-1 infection. 
Bacillus Calmette-Guérin may have similar NSEs [7], and, in 
Denmark, smallpox vaccine and BGC vaccine were phased 
out at the same time, and effects were difficult to disentangle. 
Therefore, we examined whether BCG and smallpox vaccine 
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were associated with a lower prevalence of HIV-1 in Guinea-
Bissau and Denmark.
METHODS
Our research comprises a cross-sectional study from Guinea-
Bissau and a case-based study from Denmark.
The Cross-Sectional Study From Guinea-Bissau
The Bandim Health Project maintains a health and demo-
graphic surveillance system in Guinea-Bissau. This includes 
registration of all pregnancies and childbirths as well as a full 
census of the total study population every 2 or 3  years. The 
cohort from Guinea-Bissau was surveyed in an HIV preva-
lence survey (2004–2006) followed by a vaccination scar survey 
(2005–2007).
The “HIV prevalence survey” was conducted in 3 districts 
between May 2004 and December 2006. The study included 
384 randomly selected houses (10% sample of houses), and all 
individuals aged 15 years or older in these houses were inter-
viewed [8]. There was a parituclar focus on older individuals; 
therefore, the survey also included individuals aged 50 years or 
older who lived in houses that were not included in the ran-
dom sample of houses. In total, 79% of eligible individuals had 
HIV status examined [8]. Similar to previous surveys, the pro-
portion of HIV-tested individuals was higher among women 
(85%) than men (71%) [8]. Antiretroviral treatment was not 
generally available in Bissau when the survey was conducted. 
The National Laboratory in Guinea-Bissau used Enzygnost 
HIV-1/HIV-2 Plus ELISA (Behring, Marburg, Germany) to 
screen for HIV-1 and HIV-2 infection. Confirmation of positive 
sera was performed using Capillus HIV-1/HIV-2 (Cambridge 
Biotech Limited, Galway, Ireland) and Immunocomb II HIV-1 
and -2 BiSpot RST (Orgenics, Yavne, Israel) [8]. We analyzed 
HIV-1-positive tests.
The “vaccination scar survey” was conducted between 
January 2005 and May 2007. Three field workers examined 
vaccination scars and interviewed study participants. The field 
workers examined upper arms for scars and registered up to 5 
scars. Scars were classified as BCG, smallpox vaccination, or 
uncertain based on size, color, and general appearance of the 
scar. The circumference of the scar was marked with a pen: 
transparent adhesive tape was placed over the marking and then 
transferred to the questionnaire.
The questionnaires from the HIV survey and the vaccination 
scar survey were double entered, and scar sizes were assessed 
by the same data entry clerk. The scar size was calculated as the 
mean of the sum of the diameters. Sixty-two (3.5%) individuals 
had a difference in birth date of more than 5 years in the 2 sur-
veys, and this was mostly among the elderly. We considered the 
scar survey to be most correct and retrieved year of birth from 
this source. The scar survey questionnaire included background 
information on year of birth, sex, field worker, place of birth, 
schooling, religion, ethnicity, employment (private sector, state 
sector, or military services), travels abroad, and living outside 
Guinea-Bissau before 1980. Census information about quality 
of house (zinc roof, electricity, indoor toilet) and ownership of 
television was used to define a socioeconomic status variable 
(0–4 items).
The Case-Based Study From Denmark
The case-based study from Denmark used a background cohort 
of all children born in 1965–1976 and attending school in 
Copenhagen. This cohort experienced the phase out of BCG 
and smallpox vaccinations from the Danish vaccination pro-
gram (vaccination policies are explained elsewhere [7]). School 
health examination records were archived in the Copenhagen 
Municipal Archives with personal identification numbers (ID) 
and information on anthropometry, social and health condi-
tions, and vaccinations. The ID enabled us to link individu-
als to national vital and health registers. We sampled all HIV 
cases in the entire background cohort (Figure 1), as identified 
from the Danish National Patient Registry (DNPR) using the 
following International Classification of Diseases (ICD) codes: 
07983 (ICD-8, 1983–1993) and B20-B24 (ICD-10 from 1994 
onwards). More than 99.7% of Danish HIV cases are HIV-1, 
and the Danish healthcare system provides free HIV treatment 
[9]. Vaccination information and potential confounders were 
digitalized from the school health records for all cases and 
compared with already digitalized information from a subco-
hort comprising 13% of the background cohort. Vital informa-
tion (ie, date of birth, death, and emmigration) came from the 
Danish Civil Registration System.
Sexually Transmitted Human Immunodeficiency Virus-1 
The route of transmission may be important to understand 
whether BCG and smallpox vaccination have effects against 
HIV-1 infection. Human immunodeficiency virus-1 is almost 
exclusively sexually transmitted in Guinea-Bissau: injection 
drug use is virtually nonexistent in Guinea-Bissau [10], and 
blood transfusions have been screened for HIV since 1987 [8]. 
In Denmark, blood transfusions was screened for HIV since 
1986, and injection drug use is a common cause of HIV-1 [9]. 
For similarity, in the Danish data, we excluded individuals if 
they were registered with diagnoses indicating injection drug 
use in DNPR during follow up.
Statistical Analyses
For both studies, we present the potential risk factors for being 
smallpox and BCG vaccinated as prevalence ratios (PRs) 
adjusted for sex and year of birth using Poisson regression with 
robust variance estimates [11]. Logistic regression models were 
used to estimate the odds ratio (OR) for the association between 
vaccination scar status and HIV-1 infection. Assuming a causal 
structure, we identified potential confounders in the fully 
adjusted models, which included year of birth in 10-year inter-
vals, sex, field worker, place of birth, schooling, religion, ethni-
city, employment, socioeconomic status, traveled abroad, and 
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lived abroad (Guinea-Bissau) or family social class, sex, immi-
gration, and year of birth (Denmark). We accounted for house 
clustering in the study from Guinea-Bissau and for the sam-
pling approach related to sex and year of birth for the Danish 
study with robust variance estimates [6]. For the Danish study, 
we calculated the association in adjusted OR (aOR) by apply-
ing a case-base design [12]. Missing information about family 
social class was single imputed for 4 HIV cases and 256 non-
HIV cases to prevent bias occurring from restricting the cohort 
to individuals with full information. Entry was at 15  years of 
age or January 1, 1983 (when HIV/acquired immune deficiency 
syndrome was part of ICD-8), whichever occurred last. End 
of follow up was the last update of the DNPR (December 31, 
2014). Individuals were censored if they had ever been regis-
tered with injection drug use, emigrated, died, or had unknown 
whereabouts according to the Danish Civil Registration System 
during follow up and before HIV-1 registration. We used (1) 
inverse probability-of-censoring weighting (IPCW) based on 
potential common causes to exposure and (2) censoring among 
controls to handle non-HIV censoring before end of follow up 
[13]. The results from both studies were combined in random 
effect meta-estimates, interpreted as an average of different true 
effects between studies [14].
Previous studies have shown that the beneficial effect of 
smallpox vaccination on mortality increased with the num-
ber of smallpox vaccination scars [15]; therefore, we tested the 
effect of multiple smallpox vaccination scars in the Guinea-
Bissau study. Information on the number of smallpox vaccines 
was not available in the Danish data.
We conducted several analyses to test the robustness of the 
conclusions. At the exploratory stage, P values should not be 
“corrected” for multiple testing [16]. In our complementary 
analysis of Guinean and Danish data, we used a stabilized 
inverse probability of treatment weighted model (sIPTW) to 
give association measures closer to a randomized controlled 
trial in a similar population (see additional information in 
Supplementary Analysis 1) [13]. As a supplementary analysis to 
the Danish study, we conducted the commonly reported hazard 
ratio using a Cox proportional hazards model for case-cohorts 
with age as the underlying time scale to estimate the hazard ratio 
(HR) of HIV-1 by BCG and smallpox vaccination status. The 
proportional hazards assumption was tested with Schoenfeld 
residuals. All statistical analyses were conducted using Stata 
14.1 (StataCorp LP, College Station, TX).
Ethics
The HIV survey and the vaccination scar survey in Guinea-
Bissau were approved by the Ministry of Health’s Ethics 
Committee in Guinea-Bissau, and the Danish Central Scientific 
Ethics Committee gave its consultative approval. All partic-
ipants were counseled and provided informed verbal consent 
before HIV testing [8]. The field workers conducting the sur-
veys were not aware of the HIV status of the participants. The 
Danish Data Protection Agency approved the Danish study: 
registry-based research does not require approval by an ethics 
committee in Denmark.
RESULTS
The Guinea-Bissau study included 1751 individuals with 75 
HIV-1 cases (Figure 1), and the analyzed study population in 
Denmark was derived from an eligible background cohort of 
46 239 individuals, using 5506 individuals as a subcohort with 
104 HIV-1 cases (Figure 1).
Guinea-Bissau
Two thousand three hundred six individuals born before 
January 1, 1974 were eligible for this study, because they had a 
probability of being smallpox vaccinated (Figure 1). On aver-
age, there was more than 1 year between the HIV survey and the 
subsequent scar examination, thus 1751 individuals (76% of the 
eligible population) were analyzed (Figure 1). The prevalence 
of HIV-1 was 4.3% in both the analyzed study population and 
the eligible population. Seventy-five of the included individu-
als were HIV-1 infected. The female/male prevalence ratio of 
HIV-1 was 1.53 (0.97–2.42), and 5% women and 3% men were 
infected with HIV-1. Supplementary Figure 1 shows the age dis-
tribution of HIV-1-positive individuals.
In the population included in the study, 22% (393) had no 
vaccination scars, 46% (808) had smallpox vaccination scars 
only, 11% (191) had BCG vaccination scars only, and 21% (359) 
had both BCG and smallpox vaccination scars. The median 
diameter of scars classified as smallpox scars was 15.0  mm 
(25–75 percentiles: 11.5–19.3) and 5.0 mm (25–75 percentiles: 
4.0–6.5 mm) for BCG vaccination. Sixty-eight percent of men 
and 66% of women had a smallpox vaccination scar (10-year 
age interval adjusted PR  =  0.99 [0.77–1.18]), whereas 32% of 
men and 31% of women had BCG vaccination scars (10-year 
age interval adjusted PR = 0.92 [0.78–1.09]) (Table 1). Twenty-
five percent (445 of 1751) of the study population had 2 or more 
smallpox vaccination scars.
Individuals with smallpox and/or BCG vaccination scars had 
a lower prevalence of HIV-1 compared with individuals with-
out smallpox and BCG vaccination scars (aOR = 0.62; 95% con-
fidence interval [CI], 0.36–1.07) (Table  3). Multiple smallpox 
vaccination scars were associated with a lower prevalence of 
HIV-1 (aOR = 0.27; 95% CI, 0.10–0.75) compared with indi-
viduals without smallpox or BCG vaccination scars. The aOR 
for multiple smallpox vaccination scars was 0.18 (95% CI, 0.05–
0.64) for women and 0.52 (95% CI, 0.12–2.33) for men (sex-dif-
ferential effect, P = .29) (Table 4).
Denmark
The eligible background cohort of 46 239 individuals had 143 
HIV-1 cases, and the 13% subsample was equivalent to 6015 
individuals. We excluded 39 (27%) HIV-1 cases and 509 (8%) 
individuals in the subcohort for reasons indicated in Figure 1. 
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Hence, 104 HIV-1 cases were analyzed (21 women, 83 men) 
along with a subcohort of 5506 of individuals. Among these, 
18% (996) had no vaccination, 7% (402) had smallpox vacci-
nation only, 27% (1491) had BCG vaccination only, and 48% 
(2617) had both BCG and smallpox vaccination (Table  2). 
Smallpox vaccinated individuals were more likely to be BCG 
vaccinated, and those having all other childhood vaccinations 
was positively associated with both smallpox and BCG vaccina-
tion (Table 2). The prespecified potential confounders, immi-
grants and family social class, were associated with BCG and 
smallpox vaccination, and more women had smallpox vaccines 
than men (Table 2).
During follow up, 9% of individuals were censored in the 
subcohort (emigration, 6%; death, 2%; unknown whereabouts, 
0.3%). To correct the study population for non-HIV-positive 
individuals leaving the study before end of follow up, we used 
inverse probability of censoring weights, which resulted in a 
weighted subcohort of ~5506. Bacillus Calmette-Guérin and/or 
smallpox vaccination was associated with an IPCW aOR of 0.70 
(95% CI, 0.43–1.15) for having HIV-1 compared with neither of 
these (Table 3).
Combined Estimate
The combined meta-estimate from both study locations for 
BCG and/or smallpox scars/vaccinations compared with none 
of these vaccines gave an aOR of 0.66 (95% CI, 0.46–0.96) 
(Table 3). The estimate for women was an aOR of 0.52 (95% CI, 
0.32–0.84); the estimate for men was an aOR of 0.77 (95% CI, 
0.48–1.24) (sex-differential effect, P = .26).
Sensitivity Analyses
We tested for an association with any smallpox and BCG vac-
cination scar versus none of these in the alternative analyses 
using inverse probability of treatment weights and found simi-
lar results in both Guinea-Bissau and Denmark (Supplementary 
Table 1). The Cox proportional hazard estimate in the Danish 
study indicated a similar association to the IPCW logistic regres-
sion, but the result should be interpreted cautiously because the 
test for proportional hazards was 0.05 (Supplementary Table 1).
DISCUSSION
Our studies from 2 very different settings suggest that small-
pox and/or BCG vaccinations were associated with a lower 
Eligible study population
2306 individuals [99 HIV-1 cases]
Exclusion of 1613 Individuals born after1st of January
1974 not oered smallpox vaccinated
Study population
3919 participants in the HIV survey with known HIV status
[152 HIV-1 cases]
All HIV-1 cases 
143 individuals
Sub-cohort(including HIV cases within the
sub-cohort)
6015 (19 HIV-1 cases)
54 individuals received no questionnaires by mistake
Exclusion of 9 individuals with missing scar status
Exclusion of 10 individuals with missing information
about schooling, employment, and socio-economic
status
Exclusion of 2 individuals who refused to take part
No exclusion of HIV-1 cases due to
no observation time after start of
follow up
Exclusion of 146 individuals lost to follow 
up (2), emigrated (136) or died (8) before 
end of follow up (0 HIV-1 cases)
Exclusion of 9 duplicates
Exclusion of 177 individuals who moved before scar 
survey
Exclusion of 56 individuals who died before scar survey
Exclusion of 238 individuals who were travelling / absent
at day of visit: 238
Exclusion of 224 individuals without
information of atleast one childhood
vaccine (0 HIV-1 cases)
Exclusion of 1 HIV-1 casewithout 
information of atleast one childhood
vaccine
Exclusion of 17 individuals with a missing 
school health record (1 HIV-1 case)
Exclusion of 74 individuals with an invalid 
ID (0 HIV-1 cases)No HIV-1 cases with an invalid ID
Study population
75 HIV-1 cases in a cohort of 1751individuals
Exclusion of 12 HIV-1 cases with a
missing school health record
Study population
104 HIV cases in total (13 within the sub-cohort, and 91 outsidethe sub-cohort)
5506 individuals in the baseline sub-cohort (the IPCW sub-cohort was ~5506)
Single imputation of: 253 individuals 
without family social class (0 HIV-1 cases)
Single imputation of 4 HIV-1 cases 
with missing family social class
Inverse probability weighting of censoring 
for 469 non-HIV-1 censorings during 
follow up.
Exclusion of 26 HIV-1 cases who had 
injection drug use registered before 
HIV diagnosis.
Exclusion of 48 individuals who had 
injection drug use registered during follow 
up. (5 HIV-1 cases)
Exclusion of 1383 individuals with 
missing ID
Eligible background cohort
46239 individuals with an ID
Background cohort
47622 individuals in the Copenhagen School Health Record Registerborn1965-76
A B
Figure 1. Flow chart of the study population in (A) Guinea-Bissau and (B) Denmark.
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Table 1. Baseline Variables by Smallpox and BCG Vaccination Scar Status in Guinea-Bissau
n = 1751
Smallpox Vaccination Scar BCG Vaccination Scar
No Smallpox 
Vaccination Scars
Smallpox 
Vaccination Scars
aPR (95% CI)a P Valueb
No BCG Vaccination 
Scars
BCG Vaccinaion 
Scars
aPR (95% CI)a P Valuebn (%) n (%) n (%) n (%)
Sex
 Male 218 (32%) 469 (68%) 1 (ref) .81 464 (68%) 223 (32%) 1 (ref) .35
 Female 366 (34%) 698 (66%) 0.99 (0.88–1.11) 737 (69%) 327 (31%) 0.92 (0.78–1.09)
BCG Vaccination Scar
 No 393 (33%) 808 (67%) 1 (ref) .76
 Yes 191 (35%) 359 (65%) 1.02 (0.90–1.16)
Smallpox Vaccination Scar
 No 393 (67%) 191 (33%) 1 (ref) .65
 Yes 808 (69%) 359 (31%) 1.04 (0.86–1.26)
Assistent
 A 108 (28%) 279 (72%) 1 (ref) .04 266 (69%) 121 (31%) 1 (ref) <.01
 B 424 (36%) 739 (64%) 0.86 (0.75–0.98) 834 (72%) 329 (28%) 0.96 (0.78–1.18)
 C 52 (26%) 149 (74%) 1.01 (0.83–1.23) 101 (50%) 100 (50%) 1.63 (1.25–2.12)
Birth Place
 Bissau city 215 (39%) 341 (61%) 1 (ref) .47 369 (66%) 187 (34%) 1 (ref) .76
 Elsewhere 369 (31%) 826 (69%) 1.05 (0.92–1.19) 832 (70%) 363 (30%) 0.97 (0.81–1.16)
School level
 No school 263 (33%) 530 (67%) 1 (ref) .13 603 (76%) 190 (24%) 1 (ref) <.01
 Primary 136 (27%) 377 (73%) 1.15 (0.99–1.33) 353 (69%) 160 (31%) 1.26 (1.01–1.58)
 Secondary 185 (42%) 260 (58%) 1.16 (0.96–1.40) 245 (55%) 200 (45%) 1.51 (1.17–1.95)
Religion
 Animist 125 (35%) 232 (65%) 1 (ref) .30 274 (77%) 83 (23%) 1 (ref) .10
 Catholic or 
Protestant
195 (30%) 464 (70%) 1.14 (0.97–1.34) 429 (65%) 230 (35%) 1.35 (1.04–1.73)
 Muslim 75 (36%) 134 (64%) 1.03 (0.83–1.28) 134 (64%) 75 (36%) 1.37 (1.00–1.88)
 Other 189 (36%) 337 (64%) 1.03 (0.87–1.21) 364 (69%) 162 (31%) 1.19 (0.91–1.55)
Ethnicity
 Papel 280 (34%) 542 (66%) 1 (ref) .04 575 (70%) 247 (30%) 1 (ref) .81
 Manjaco 52 (24%) 165 (76%) 1.17 (0.99–1.40) 145 (67%) 72 (33%) 1.10 (0.84–1.43)
 Balanta 86 (46%) 103 (54%) 0.82 (0.66–1.01) 124 (66%) 65 (34%) 1.10 (0.84–1.45)
 Other 166 (32%) 357 (68%) 1.04 (0.91–1.19) 357 (68%) 166 (32%) 1.07 (0.88–1.31)
Work
 Unemployed 270 (37%) 454 (63%) 1 (ref) .41 510 (70%) 214 (30%) 1 (ref) .51
 Employed 228 (35%) 416 (65%) 1.05 (0.92–1.20) 424 (66%) 220 (34%) 1.01 (0.84–1.23)
 Militaty 34 (32%) 73 (68%) 1.00 (0.77–1.30) 69 (64%) 38 (36%) 1.23 (0.85–1.78)
 State-employed 52 (19%) 224 (81%) 1.16 (0.97–1.40) 198 (72%) 78 (28%) 1.21 (0.90–1.64)
SES
 0 160 (38%) 258 (62%) 1 (ref) .23 304 (73%) 114 (27%) 1 (ref) .07
 1 317 (35%) 593 (65%) 1.05 (0.91–1.21) 627 (69%) 283 (31%) 1.17 (0.94–1.46)
 2 69 (27%) 184 (73%) 1.16 (0.96–1.41) 162 (64%) 91 (36%) 1.37 (1.04–1.80)
 3 25 (24%) 80 (76%) 1.19 (0.92–1.53) 62 (59%) 43 (41%) 1.57 (1.11–2.24)
 4 13 (20%) 52 (80%) 1.31 (0.97–1.76) 46 (71%) 19 (29%) 1.11 (0.68–1.80)
Travel Abroad
 No 560 (34%) 1092 (66%) 1 (ref) .66 1133 (69%) 519 (31%) 1 (ref) .48
 Yes 24 (24%) 75 (76%) 1.06 (0.83–1.34) 68 (69%) 31 (31%) 1.14 (0.79–1.66)
Living Outside of Guinea-Bissau
 No 547 (34%) 1051 (66%) 1 (ref) .29 1104 (69%) 494 (31%) 1 (ref) .24
 Yes 37 (24%) 116 (76%) 1.11 (0.91–1.35) 97 (63%) 56 (37%) 1.18 (0.89–1.56)
Abbreviations: aPR, annual percentage rate; BCG, Bacillus Calmette-Guérin; CI, confidence interval; ref, reference group; SES, socioeconomic status.
aPrevalence ratios and 95% CIs are estimated by Poisson regression adjusted for sex and year of birth in 10-year intervals with robust estimation of variance clustered by house 
bWald test.
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prevalence of HIV-1 when combining the evidence from 
Guinea-Bissau and Denmark. The pattern was consist-
ent across all combinations of smallpox and BCG vaccina-
tions, but estimates from comparison groups with smaller 
samples had high uncertainty. The indication that multiple 
smallpox vaccination scars were associated with an add-
itionally lower aOR of being HIV-1 infected compared with 
individuals without any vaccinationscars in the study from 
Guinea-Bissau, where this information was available, suggest 
a biological dose response relationship. Although not statis-
tically significant, the association tended to be stronger for 
women than for men; the beneficial effect of smallpox vacci-
nation on adult mortality in Guinea-Bissau was also stronger 
for women than for men [4, 5].
Table 2. Baseline Variables by Smallpox and BCG Vaccination Status Among the Baseline Subcohort in Denmark
n = 5506
Smallpox Vaccination BCG Vaccination
No Smallpox 
Vaccination
Smallpox 
Vaccination
aPR (95% CI)a P Valueb
No BCG 
Vaccination BCG Vaccinaion
aPR (95% CI)a P Valuebn (%) n (%) n (%) n (%)
Sex
 Men 1306 (47%) 1471 (53%) 1 (ref) 0.07 708 (25.5%) 2069 (74.5%) 1 (ref) .96
 Women 1181 (43.3%) 1548 (56.7%) 1.07 (0.99–1.15) 690 (25.3%) 2039 (74.7%) 1 (0.94–1.06)
BCG
 No 996 (71.2%) 402 (28.8%) 1 (ref) <.01
 Yes 1491 (36.3%) 2617 (63.7%) 1.22 (1.1–1.36)
Smallpox Vaccination
 No 996 (40%) 1491 (60%) 1 (ref) <.01
 Yes 402 (13.3%) 2617 (86.7%) 1.16 (1.06–1.26)
Other Childhood Vaccinations but Smallpox and BCG Registered
 All other recommended 1789 (46.9%) 2025 (53.1%) 1 (ref) <.01 922 (24.2%) 2892 (75.8%) 1 (ref) <.01
 Some other 
recommended
626 (41.1%) 897 (58.9%) 0.87 (0.81–0.95) 440 (28.9%) 1083 (71.1%) 0.87 (0.81–0.94)
 None other 72 (42.6%) 97 (57.4%) 0.79 (0.64–0.97) 36 (21.3%) 133 (78.7%) 0.93 (0.78–1.11)
Eczema
 No or missing 2289 (44.2%) 2890 (55.8%) 1 (ref) .15 1284 (24.8%) 3895 (75.2%) 1 (ref) .27
 Yes 198 (60.6%) 129 (39.4%) 0.88 (0.74–1.05) 114 (34.9%) 213 (65.1%) 0.93 (0.81–1.06)
Immigration
 No 2331 (44.2%) 2938 (55.8%) 1 (ref) <.01 1298 (24.6%) 3971 (75.4%) 1 (ref) .01
 Yes 156 (65.8%) 81 (34.2%) 0.69 (0.56–0.87) 100 (42.2%) 137 (57.8%) 0.81 (0.68–0.96)
Family Social Class
 I 196 (51.9%) 182 (48.1%) 1 (ref) .18 113 (29.9%) 265 (70.1%) 1 (ref) .33
 II 310 (47.5%) 343 (52.5%) 0.98 (0.82–1.18) 138 (21.1%) 515 (78.9%) 1.07 (0.92–1.24)
 III 368 (42%) 509 (58%) 0.97 (0.82–1.14) 201 (22.9%) 676 (77.1%) 1.02 (0.89–1.18)
 IV 772 (41.6%) 1084 (58.4%) 0.95 (0.81–1.11) 418 (22.5%) 1438 (77.5%) 1.03 (0.9–1.17)
 V 486 (41.8%) 676 (58.2%) 0.91 (0.77–1.07) 307 (26.4%) 855 (73.6%) 0.96 (0.83–1.1)
 Unclassifiable 178 (54.4%) 149 (45.6%) 0.78 (0.63–0.97) 100 (30.6%) 227 (69.4%) 0.93 (0.78–1.12)
 Missing (imputed for 
analysis)
177 (70%) 76 (30%) Not calculated 121 (47.8%) 132 (52.2%) Not calculated
Siblings
 None 382 (48.6%) 404 (51.4%) 1 (ref) .33 224 (28.5%) 562 (71.5%) 1 (ref) .07
 One 1178 (44.2%) 1488 (55.8%) 1.03 (0.92–1.15) 603 (22.6%) 2063 (77.4%) 1.05 (0.96–1.15)
 Two or more 809 (44.4%) 1012 (55.6%) 0.97 (0.86–1.09) 503 (27.6%) 1318 (72.4%) 0.97 (0.88–1.07)
 Missing (imputed for 
analysis)
118 (50.6%) 115 (49.4%) Not calculated 68 (29.2%) 165 (70.8%) Not calculated
Daycare Before School
 No 422 (35.3%) 773 (64.7%) 1 (ref) .71 293 (24.5%) 902 (75.5%) 1 (ref) .12
 Yes 1854 (50.6%) 1807 (49.4%) 0.98 (0.9–1.07) 947 (25.9%) 2714 (74.1%) 1.06 (0.98–1.15)
 Missing (imputed for 
analysis)
211 (32.5%) 439 (67.5%) Not calculated 158 (24.3%) 492 (75.7%) Not calculated
Abbreviations: aPR, annual percentage rate; BCG, Bacillus Calmette-Guérin; CI, confidence interval; ref, reference group.
aPrevalence ratios and 95% CIs are estimated by Poisson regression adjusted for sex and year of birth.
bWald test.
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Strengths and Limitations
Because there is no central register of smallpox vaccinations in 
Guinea-Bissau, we relied on reading smallpox and BCG vaccina-
tion scars to determine vaccination status. In a small validation 
study in the capital, 90% (62 of 69)  of Bandim residents with a 
smallpox vaccination identified in the city register had a smallpox 
vaccination scar, which was identified by field workers in the study 
area; a few minor scars were missed [4]. Misclassified smallpox 
vaccination scars can lead to conservative estimates. Unfortunately, 
we cannot check whether the individuals censored between the 
HIV survey and the subsequent vaccination scar survey differed 
with regard to confounders relevant to the scar survey. As in 2 pre-
vious scar surveys, there was some variation in how fieldworkers 
measured the size of the scar [4, 5]; however, the fieldworkers con-
ducting the scar survey were not involved in the HIV survey.
The main concerns in the Guinean study are the potential 
common causes for “not” having smallpox and BCG vaccina-
tion scars and to acquire HIV-1. We adjusted for 11 potential 
confounders that we think cover social mechanisms for vacci-
nation and HIV-1, but we cannot exclude residual confound-
ing. The study population was examined for vaccination scars 
in 2005–2007 and in relation to the HIV-survey cohort in 
2004–2006; therefore, only a selected population survived until 
then. If HIV-1-infected individuals with several smallpox vac-
cination scars died more rapidly before follow-up than HIV-1-
infected individuals without scars, then this could explain the 
estimate we found. However, we know from previous follow-up 
studies that individuals with several smallpox vaccination scars 
have significantly better survival rates [4]. The study popula-
tion included a higher proportion of elderly patients due to 
the sampling approach, but this would not affect the estimates 
(assuming an age-homogeneous effect) because all analyses 
were stratified by 10-year age intervals.
For the Danish study, both BCG and smallpox vaccinations 
were given long before the individuals contracted HIV-1, which 
ensures temporality. We cannot be certain that all the included 
HIV-1 cases were related to sexual transmission because injec-
tion drug use is underreported in Danish health registries.
We used the complementary sIPTW analyses, which sup-
ported the main conclusion. The 2 studies differ on several 
conditions: the measurement of vaccination (health record vs 
scar read), the study population’s characteristics, climate, HIV-1 
infection pressure, competing diseases, and social interac-
tions. We interpret the consistent pattern across such different 
Table 3. BCG and Smallpox Vaccination and HIV-1 in Guinea-Bissau and Denmark: Separate and Combined Estimates
Smallpox/BCG 
Vaccinated
Guinea-Bissau (GB) Denmark (DK) Combined Estimatee
% (HIV/All)
Adjusted ORa  
(95% CI) IPCW % (HIV/Allb)c
IPCW and Adjusted  
ORd (95% CI) GB Weight DK Weight
Combined Estimate of 
Adjusted ORs
All
 −/− 6.1% (24/393) 1 (ref) 1.6% (16/1011.9) 1 (ref) - - 1 (ref)
 +/− 3.3% (27/808) 0.72 (0.39–1.33) 1.5% (6/407.6) 0.52 (0.17–1.60) 77% 23% 0.67 (0.39–1.14)
 −/+ 4.7% (9/191) 0.50 (0.23–1.10) 1.5% (22/1511.4) 0.70 (0.41–1.18) 31% 69% 0.63 (0.41–0.98)
 +/+ 4.2% (15/359) 0.59 (0.28–1.25) 2.3% (60/2665.7) 0.74 (0.44–1.26) 33% 67% 0.69 (0.45–1.06)
 Either or 3.8% (51/1358) 0.62 (0.36–1.07) 1.9% (88/4584.7) 0.70 (0.43–1.15) 45% 55% 0.66 (0.46–0.96)
Women
 −/− 6.9% (17/247) 1 (ref) 1.0% (5/492.3) 1 (ref) - - 1 (ref)
 +/− 3.7% (18/490) 0.64 (0.30–1.36) 1.0% (2/202.6) 0.53 (0.12–2.35) 79% 21% 0.61 (0.31–1.21)
 −/+ 7.6% (9/119) 0.73 (0.31–1.71) 0.6% (4/697.8) 0.45 (0.13–1.59) 67% 33% 0.62 (0.31–1.26)
 +/+ 4.8% (10/208) 0.56 (0.23–1.36) 0.7% (10/1353.6) 0.37 (0.17–0.81) 44% 56% 0.43 (0.25–0.78)
 Either or 4.5% (37/817) 0.63 (0.33–1.21) 0.7% (16/2254.0) 0.40 (0.19–0.82) 56% 44% 0.52 (0.32–0.84)
Men
 −/− 4.8% (7/146) 1 (ref) 2.1% (11/519.5) 1 (ref) - - 1 (ref)
 +/− 2.8% (9/318) 0.90 (0.32–2.51) 2.0% (4/204.9) 0.51 (0.12–2.07) 66% 34% 0.74 (0.32–1.71)
 −/+ 0% (0/72) N/A 2.2% (18/814.0) 0.82 (0.48–1.38) N/A N/A N/A
 +/+ 3.3% (5/151) 0.62 (0.16–2.37) 3.8% (50/1311.9) 0.92 (0.49–1.70) 18% 82% 0.86 (0.49–1.51)
 Either or 2.6% (14/541) 0.60 (0.23–1.55) 3.1 (72/2330.7) 0.84 (0.49–1.45) 24% 76% 0.77 (0.48–1.24)
Abbreviations: BCG, Bacillus Calmette-Guérin; CI, confidence interval; DK, Denmark; GB, Guinea-Bissau; HIV, human immunodeficiency virus; IPCW, inverse probability of censoring 
weighted; NA, nonapplicable; OR, odds ratio; ref, reference group. 
aLogistic regression adjusted for year of birth in 10-year intervals, sex, field worker, place of birth, schooling, religion, ethnicity, employment, socioeconomic status, traveled abroad, and 
lived abroad and stratified by house with robust variance.
bNon-HIV cases are weighted by the inverse probability of being censored during follow up.
cNote the percentages cannot be interpreted as the prevalence of HIV-1, because only a subcohort of the background cohort is included in the denominator, whereas all HIV-1 cases in the 
background cohort are included in the numerator (an estimation of the prevalence is given in Supplementary Table 1). Because the cohort was sampled by birth year and vaccination cover-
age decreases with time, the percentage of HIV cases cannot directly be compared among vaccination groups.
dLogistic regression adjusted for family social class, sex, immigration, year of birth and weighted by the inverse probability of being censored during follow-up and with robust variance 
clustered by birth year and sex.
eThe combined adjusted odds ratios from Denmark and Guinea-Bissau were combined in random effect meta-estimates.
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studies to suggest an underlying causal effect. Our random 
effects meta-analysis estimate should not be interpreted as an 
effect of 1 well defined intervention, but rather a combination 
of effects occurring across different settings, where one would a 
priori expect different effects.
Consistency With Other Studies
When the smallpox vaccination was first introduced, several 
reports suggested that it prevented more than smallpox infec-
tion [17]. Very few formal studies of associations between 
smallpox vaccination and (non-smallpox) mortality and mor-
bidity have been conducted, but they have consistently found 
that smallpox vaccination is associated with improved general 
health. In high-income countries, smallpox vaccination was 
associated with fewer infectious disease hospital admissions [6] 
and less risk of asthma [18], multiple sclerosis [19], and some 
cancers [20–24]. In Denmark, having documented BCG and 
smallpox vaccinations at school was associated with reduced 
mortality by 46% (range, 19%–64%) in up to 40 years after vac-
cination [7].
Increasing evidence suggests that the nonspecific effects of 
BCG vaccination are more pronounced if BCG-vaccinated 
individuals develop a BCG scar [25–29]. Smallpox and BCG 
vaccination status were assessed by scar status in the study from 
Guinea-Bissau, whereas it was assessed by recorded vaccina-
tion dates in the Danish study. This might have influenced the 
lower point estimate for HIV-1 by smallpox and/or BCG vacci-
nation (scars) in Guinea-Bissau of 0.62 compared with 0.70 in 
Denmark (due to low power, we cannot rule out that this result 
could be due to chance) (Table 3).
In 2 studies from Guinea-Bissau, smallpox vaccination scars 
were associated with better survival [4, 5], a beneficial associa-
tion that also increased with the number of vaccination scars, 
as we observed in the present study. Multiple studies indicate 
a beneficial boosting effect on nonspecific outcomes from 
revaccination with the same live vaccines [15], corroborating 
our finding that multiple smallpox vaccination scars were asso-
ciated with an additionally lower prevalence ratio of HIV-1 in 
our study in Guinea-Bissau (Table  4). Because smallpox and 
BCG vaccination may have different mechanisms for a poten-
tial reduced risk of HIV-1, several different live vaccines could 
be expected to be associated with a lower risk of HIV-1, com-
pared with having received 1 live vaccine. However, we did not 
observe a lower effect by having received both smallpox and 
BCG vaccination compared with 1 of the 2 in either the study 
from Guinea-Bissau or Denmark (Table 3).
Possible Biological Mechanisms
The nonspecific effects of vaccines challenge our current 
understanding of the immune system, which considers only 
the pathogen-specific effects of vaccination. The immunolog-
ical mechanisms underlying nonspecific effects are still largely 
unknown, but new evidence is emerging. In brief, nonspecific 
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effects may occur via effects on the innate immune system, the 
adaptive immune system, or both [2]. With respect to the innate 
immune system, BCG may induce epigenetic modifications of 
innate immune cells, leading to long-lasting innate immune 
memory [3]. Very recent in vitro studies indicate that small-
pox vaccine induces similar “innate training”, which increases 
cytokine responses of monocytes to unrelated stimuli. There 
are possible benefits associated with this immune activation; 
however, it was recently observed that BCG was associated with 
increased simian immunodeficiency virus (SIV) acquisition in 
infant macaques, leading to speculation that the BCG-induced 
immune activation could have facilitated SIV infection [30].
For the adaptive immune system, cross-reactive epitopes can 
lead to the formation of cross-reactive T-memory cells, which 
can induce long-lasting heterologous T cell-mediated immu-
nity [31]. The vaccinia virus used for the smallpox vaccination 
shows homologs of the HIV-1 envelope glycoprotein, suggest-
ing a potential for cross-reactive immunity [32]. We know that 
several viruses interact with and inhibit HIV-1 replication and 
sometimes alter the course of infection and prolong survival of 
HIV-1 infected individuals [33–36].
Pathogens typically invade the host through epithelial inter-
faces with the environment. Intriguingly, both smallpox and 
BCG vaccination are given directly in the skin. In animal mod-
els, administering smallpox vaccination via skin scarification 
increased immune response and survival upon subsequent 
challenge compared with other modes of administration [37]. It 
has been shown in mice that localized vaccinia virus skin infec-
tion generates long-lived nonrecirculating CD8+ skin resident 
T-memory cells that resided within the entire skin and pro-
tected against reinfection [38]. Thus, although the mechanism 
is unknown, memory acquired at the site of vaccination can 
spread throughout the entire epithelial surface, which creates 
a “shield” against reinfection. We speculate that innate training 
by epigenetic modifications observed in monocytes also takes 
place at the level of epithelial progenitor cells, leading to direct 
alterations in the first-line epithelial defense system.
In order for HIV-1 to establish a primary infection, activation 
of the chemokine receptor CCR5 is important [39]. Therefore, 
it is interesting note that vaccinia virus may downregulate the 
CCR5 receptor on the surface of the T cell [40, 41]. In an ex vivo 
tonsillar tissue model, vaccinia virus depleted CCR5 T cells, 
significantly inhibiting the replication of the HIV-1 variant 
R5 [42]. Further immunological studies have supported a role 
for CCR5 in establishing smallpox infection [43]. The CCR5-
delta-32 deletion confers resistance to HIV-1 by preventing 
expression of the receptor on the cell surface. In a recent study, 
based on modeling, researchers argued that the high frequency 
of the CCR5-delta-32 deletion allele in Europe is consistent 
with a role of smallpox epidemics; the large European smallpox 
epidemics leads to selective survival advantages of individuals 
with the deletion allele [44].
Thus, it is plausible that smallpox vaccination may alter the 
expression of CCR5 on cell surfaces and/or the production of 
CCR5-specific ligands, and this may interfere with establishing 
HIV infection. Corroborating this notion, a recent US study 
found that cells from smallpox vaccinated individuals had an up 
to 5-fold reduction in CCR5 tropic HIV-1 replication in vitro 
[40, 41].
CONCLUSIONS
In conclusion, there is some immunological evidence to sup-
port that intradermally administrated smallpox vaccination 
can provide cross-protection against HIV-1 infection. None of 
the above immunological studies reported effects by sex, but 
it is well known that males and females respond immunolog-
ically different to vaccines [45], and it seems plausible that an 
enhanced epithelial protection would be particularly protective 
against vaginally acquired HIV-1 infection. This could explain 
why smallpox vaccination might be more associated with pro-
tection against HIV-1 in women than in men.
Combining the evidence from Guinea-Bissau and Denmark, 
BCG and/or smallpox vaccinations were associated with less 
sexually transmitted HIV-1. The studies were based on a few 
HIV-1 cases; however, the results are consistent with immuno-
logical studies that showed reduced HIV-1 replication in cells 
from smallpox vaccinated individuals. So far, these results sug-
gest that the mechanisms linking BCG and smallpox vaccines 
with protection against HIV-1 warrant further investigation. 
Hopefully, immunologists will investigate additional mecha-
nisms for how smallpox and BCG vaccinations could possibly 
prevent HIV-1, and why such an effect might be stronger for 
women than men. The findings, if confirmed, could have major 
implications for future interventions against HIV-1, and thus 
future prospective studies are urgently warranted.
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online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility of 
the authors, so questions or comments should be addressed to the corre-
sponding author.
Acknowledgments
We thank Professor Thorkild I.  A. Sørensen (Department of Clinical 
Epidemiology at Bispebjerg and Frederiksberg Hospital) for access to data 
and valuable comments. We are grateful to Dr. Joachim Knop (Department 
of Clinical Epidemiology at Bispebjerg and Frederiksberg Hospital) for 
advice on registration of injection drug use in the Danish National Patient 
Register.
Author contributions. A.  Ri., M.  V., and P.  A.  are guarantors of the 
study. M. L. J., A. Ri., M. V., Z. J. d., A. E. R., A. Ro., C. S. B., and P. A. contrib-
uted to the study design and collection of data from Guinea-Bissau; M. V., 
A. Ri., M. L. J., and P. A. analyzed and interpreted the data; M. V., A. Ri., 
M. L. J., C. S. B., and P. A. drafted this part of the manuscript. M. V., S. S., 
A. E. R., and A. Ri. supervised the data entry of the study from Denmark; 
M. V. and A. Ri. analyzed data and drafted this part of the manuscript. All 
authors made significant contributions to interpretation of the data and the 
final version of the manuscript. All authors declare that they had access to 
Downloaded from https://academic.oup.com/ofid/article-abstract/4/3/ofx130/3873484
by Kobenhavns Universitets user
on 10 January 2018
10 • OFID • Rieckmann et al
the data, accepted the final version of the article, and approved the submis-
sion of the final draft.
Disclaimer. The co-first authors and senior author affirm the follow-
ing: this manuscript is an honest, accurate, and transparent account of the 
study being reported; no important aspects of the study have been omitted; 
and any discrepancies from the study as planned (and, if relevant, regis-
tered) have been explained. The funding agencies had no role in the study 
design, data collection, data analysis, data interpretation or in the prepara-
tion, review, or approval of the manuscript.
Financial support. A.  Ri. received an unrestricted Faculty of 
Health Sciences scholarship from University of Southern Denmark. 
M.  V.  received an unrestricted PhD grant from the Danish Graduate 
School in Public Health Science and University of Copenhagen, 
Lundbeck Foundation (R34-A3862) and Dagmar Marshalls Foundation. 
S. S. received a grant from the Danish Council for Independent Research 
(DFF- 4183-00316). C. S. B. received funding from a European Research 
Council Starting Grant (ERC-2009-StG-243149). P. A. received a research 
professorship grant from the Novo Nordisk Foundation. Research Center 
for Vitamins and Vaccines (CVIVA) is funded by the Danish National 
Research Foundation (DNRF108). The Bandim Health Project has 
received support from the Danish International Development Agency 
(DANIDA) and European Union FP7 support for OPTIMUNISE (Grant 
Health-F3-2011-261375).
Potential conflicts of interest. All authors: No reported conflicts of 
interest. All authors have submitted the ICMJE Form for Disclosure of 
Potential Conflicts of Interest. Conflicts that the editors consider relevant to 
the content of the manuscript have been disclosed.
References
1. Strassburg MA. The global eradication of smallpox. Am J Infect Control 1982; 
10:53–9.
2. Benn CS, Netea MG, Selin LK, Aaby P. A small jab—a big effect: nonspecific 
immunomodulation by vaccines. Trends Immunol 2013; 34:431–9.
3. Netea MG, Joosten LA, Latz E, et  al. Trained immunity: a program of innate 
immune memory in health and disease. Science 2016; 352:aaf1098.
4. Aaby P, Gustafson P, Roth A, et al. Vaccinia scars associated with better survival for 
adults. An observational study from Guinea-Bissau. Vaccine 2006; 24:5718–25.
5. Jensen ML, Dave S, Schim van der Loeff M, et al. Vaccinia scars associated with 
improved survival among adults in rural Guinea-Bissau. PLoS One 2006; 1:e101.
6. Sørup S, Villumsen M, Ravn H, et al. Smallpox vaccination and all-cause infec-
tious disease hospitalization: a Danish register-based cohort study. Int J Epidemiol 
2011; 40:955–63.
7. Rieckmann A, Villumsen M, Sorup S, et al. Vaccinations against smallpox and 
tuberculosis are associated with better long-term survival: a Danish case-cohort 
study 1971–2010. Int J Epidemiol 2017; 46:695–705.
8. da Silva ZJ, Oliveira I, Andersen A, et al. Changes in prevalence and incidence 
of HIV-1, HIV-2 and dual infections in urban areas of Bissau, Guinea-Bissau: is 
HIV-2 disappearing? AIDS 2008; 22:1195–202.
9. Lohse N, Hansen AB, Jensen-Fangel S, et al. Demographics of HIV-1 infection in 
Denmark: results from the Danish HIV Cohort Study. Scand J Infect Dis 2005; 
37:338–43.
10. Månsson F. HIV-1, HIV-2, and other Sexually Transmitted Infections in Guinea-
Bissau, West Africa: Lund University; 2012.
11. Barros AJ, Hirakata VN. Alternatives for logistic regression in cross-sectional 
studies: an empirical comparison of models that directly estimate the prevalence 
ratio. BMC Med Res Methodol 2003; 3:21.
12. Pearce N. What does the odds ratio estimate in a case-control study? Int J 
Epidemiol 1993; 22:1189–92.
13. Hernán MA, Robins JM. Causal Inference. Boca Raton: Chapman & Hall/CRC, 
forthcoming; 2017.
14. Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to 
fixed-effect and random-effects models for meta-analysis. Res Synth Methods 
2010; 1:97–111.
15. Benn CS, Fisker AB, Whittle HC, Aaby P. Revaccination with live attenuated vac-
cines confer additional beneficial nonspecific effects on overall survival: a review. 
EBioMedicine 2016; 10:312–7.
16. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology 
1990; 1(1):43–6.
17. Mayr A. Taking advantage of the positive side-effects of smallpox vaccination. J 
Vet Med B Infect Dis Vet Public Health 2004; 51:199–201.
18. Bager P, Westergaard T, Rostgaard K, et  al. Smallpox vaccination and risk of 
allergy and asthma. J Allergy Clin Immunol 2003; 111:1227–31.
19. Kurtzke JF, Hyllested K, Arbuckle JD, et al. Multiple sclerosis in the Faroe Islands. 
7.  Results of a case control questionnaire with multiple controls. Acta Neurol 
Scand 1997; 96:149–57.
20. Krone B, Kölmel KF, Henz BM, Grange JM. Protection against melanoma by 
vaccination with Bacille Calmette-Guerin (BCG) and/or vaccinia: an epidemiol-
ogy-based hypothesis on the nature of a melanoma risk factor and its immuno-
logical control. Eur J Cancer 2005; 41:104–17.
21. Pfahlberg A, Kölmel KF, Grange JM, et  al. Inverse association between mela-
noma and previous vaccinations against tuberculosis and smallpox: results of the 
FEBIM study. J Invest Dermatol 2002; 119:570–5.
22. Grufferman S, Wang HH, DeLong ER, et al. Environmental factors in the etiology 
of rhabdomyosarcoma in childhood. J Natl Cancer Inst 1982; 68:107–13.
23. Lankes HA, Fought AJ, Evens AM, et  al. Vaccination history and risk of 
non-Hodgkin lymphoma: a population-based, case-control study. Cancer Causes 
Control 2009; 20:517–23.
24. Tavani A, La Vecchia C, Franceschi S, et al. Medical history and risk of Hodgkin’s 
and non-Hodgkin’s lymphomas. Eur J Cancer Prev 2000; 9:59–64.
25. Garly ML, Martins CL, Balé C, et al. BCG scar and positive tuberculin reaction 
associated with reduced child mortality in West Africa. A non-specific beneficial 
effect of BCG? Vaccine 2003; 21:2782–90.
26. Roth A, Sodemann M, Jensen H, et al. Tuberculin reaction, BCG scar, and lower 
female mortality. Epidemiology 2006; 17:562–8.
27. Roth A, Gustafson P, Nhaga A, et al. BCG vaccination scar associated with better 
childhood survival in Guinea-Bissau. Int J Epidemiol 2005; 34:540–7.
28. Timmermann CA, Biering-Sørensen S, Aaby P, et al. Tuberculin reaction and BCG 
scar: association with infant mortality. Trop Med Int Health 2015; 20:1733–44.
29. Storgaard L, Rodrigues A, Martins C, et al. Development of BCG scar and sub-
sequent morbidity and mortality in Rural Guinea-Bissau. Clin Infect Dis 2015; 
61:950–9.
30. Derrick SC. Trained immunity and susceptibility to HIV. Clin Vaccine Immunol 
2017; 24:e00509–16.
31. Welsh RM, Che JW, Brehm MA, Selin LK. Heterologous immunity between 
viruses. Immunol Rev 2010; 235:244–66.
32. Carter CJ. Vaccinia and other viruses with available vaccines show marked 
homology with the HIV-1 envelope glycoprotein: the prospect of using existing 
vaccines to stem the AIDS pandemic. Immunopharmacol Immunotoxicol 2012; 
34:222–31.
33. Moss WJ, Ryon JJ, Monze M, et  al. Suppression of human immunodeficiency 
virus replication during acute measles. J Infect Dis 2002; 185:1035–42.
34. Watt G, Kantipong P, de Souza M, et al. HIV-1 suppression during acute scrub-ty-
phus infection. Lancet 2000; 356:475–9.
35. Watt G, Kantipong P, Jongsakul K. Decrease in human immunodeficiency virus 
type 1 load during acute dengue fever. Clin Infect Dis 2003; 36:1067–9.
36. Esbjörnsson J, Månsson F, Kvist A, et al. Inhibition of HIV-1 disease progression 
by contemporaneous HIV-2 infection. N Engl J Med 2012; 367:224–32.
37. Liu L, Zhong Q, Tian T, et  al. Epidermal injury and infection during poxvirus 
immunization is crucial for the generation of highly protective T cell-mediated 
immunity. Nat Med 2010; 16:224–7.
38. Jiang X, Clark RA, Liu L, et al. Skin infection generates non-migratory memory 
CD8+ T(RM) cells providing global skin immunity. Nature 2012; 483:227–31.
39. Weber J, Piontkivska H, Quiñones-Mateu ME. HIV type 1 tropism and inhibitors 
of viral entry: clinical implications. AIDS Rev 2006; 8:60–77.
40. Rahbar R, Murooka TT, Hinek AA, et  al. Vaccinia virus activation of CCR5 
invokes tyrosine phosphorylation signaling events that support virus replication. 
J Virol 2006; 80:7245–59.
41. Weinstein RS, Weinstein MM, Alibek K, et al. Significantly reduced CCR5-tropic 
HIV-1 replication in vitro in cells from subjects previously immunized with 
Vaccinia Virus. BMC Immunol 2010; 11:23.
42. Vanpouille C, Biancotto A, Lisco A, Brichacek B. Interactions between human 
immunodeficiency virus type 1 and vaccinia virus in human lymphoid tissue ex 
vivo. J Virol 2007; 81:12458–64.
43. Rahbar R, Murooka TT, Fish EN. Role for CCR5 in dissemination of vaccinia 
virus in vivo. J Virol 2009; 83:2226–36.
44. Galvani AP, Slatkin M. Evaluating plague and smallpox as historical selective 
pressures for the CCR5-Delta 32 HIV-resistance allele. Proc Natl Acad Sci U S A 
2003; 100:15276–9.
45. Flanagan KL, Klein SL, Skakkebaek NE, et al. Sex differences in the vaccine-spe-
cific and non-targeted effects of vaccines. Vaccine 2011; 29:2349–54.
Downloaded from https://academic.oup.com/ofid/article-abstract/4/3/ofx130/3873484
by Kobenhavns Universitets user
on 10 January 2018
